CMTX-101 by Clarametyx Biosciences for Cystic Fibrosis: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CMTX-101 overview

CMTX-101 is under development for the treatment of hospital acquired pneumonia, the infections caused by enterococcus faecium, community-acquired bacterial pneumonia, staphylococcus aureus, klebsiella pneumoniae, acinetobacter baumannii, pseudomonas aeruginosa, enterobacter spp, endocarditis, chronic obstructive pulmonary disease (COPD), cystic fibrosis lung infections and pneumonia. The drug candidate is administered intravenously. The drug candidate is developed based on immune enabling technology.

Clarametyx Biosciences overview

Clarametyx Biosciences, a preclinical stage biotechnology company that developing targeted, immune-enabling biologic therapies. The company is headquartered in United States.

For a complete picture of CMTX-101’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.